Novozymes A/S

“Novonesis owns one of the most durable competitive positions in global specialty industrials — ~45-50% enzyme market share, deep customer switching costs, irreplicable fermentation expertise, and secular biological substitution tailwinds that run for decades. The Chr. Hansen merger broadens the platform and adds a high-quality food cultures segment, but has inflated goodwill, compressed ROIC to mid-teens, and introduced meaningful integration execution risk that the management team has never before navigated at this scale. At 35-45x normalized earnings, the stock prices in successful synergy delivery and resumed 6-8% organic growth with no margin for error; the most likely 10-year outcome is a 2-3x return — respectable but not exceptional given the entry price. The right action is to track closely for a better entry or integration confirmation rather than initiating a full position today.”